C 746Alternative Names: C746
Latest Information Update: 23 Oct 2014
At a glance
- Originator Cosmederm Bioscience
- Class Anti-inflammatories; Antipruritics
- Mechanism of Action Cytokine inhibitors; Substance P inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pain
Most Recent Events
- 13 Oct 2014 Phase-I clinical trials in Pain (in volunteers) in USA (Topical)